Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.20 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -17.24%. A quarter ago, it was expected that this orthopedic medical device maker would post a loss of $0.30 per share when it actually produced a loss of $0.30, delivering no surprise. Over the last four quarters ...

Core Viewpoint - Treace Medical Concepts, Inc. reported a 6% increase in revenue for Q2 2024, driven by a shift in product mix and an expanding active surgeon base, while also reaffirming its full-year revenue guidance of $201 million to $211 million, indicating growth of 7% to 13% compared to 2023 [2][3][8]. Financial Performance - Revenue for Q2 2024 was $44.5 million, up from $42.0 million in Q2 2023, reflecting a 6% increase [3]. - Gross profit for Q2 2024 was $35.7 million, compared to $34.3 million in Q2 2023, with a gross margin of 80.2%, down from 81.7% in the previous year [4]. - Total operating expenses rose to $57.1 million in Q2 2024 from $47.3 million in Q2 2023, attributed to strategic investments and increased share-based compensation [5]. Net Loss and Adjusted EBITDA - The net loss attributable to common stockholders for Q2 2024 was ($21.2) million, or ($0.34) per share, compared to a net loss of ($12.3) million, or ($0.20) per share, in Q2 2023 [6][19]. - Adjusted EBITDA loss was ($8.7) million in Q2 2024, compared to a loss of ($7.7) million in Q2 2023 [6]. Cash Position - As of June 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $97.0 million, indicating sufficient balance sheet strength to support ongoing strategic investments [7]. Patent Portfolio - The company expanded its patent portfolio to 65 granted U.S. patents, with an additional 22 granted patents worldwide and 84 pending U.S. patent applications, enhancing its competitive position in the market [2]. Future Outlook - The company plans to launch several new products in the second half of 2024, including entry into the minimally invasive metatarsal osteotomy market, aiming to capture a larger share of procedure volumes [2][8].

Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company's investor relations website at https://investors.treace.com/. Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. ...

Core Insights - Treace Medical Concepts, Inc. is participating in a fireside chat at the Truist Securities MedTech Conference on June 18, 2024, featuring CEO John T. Treace and CFO Mark L. Hair [1] Company Overview - Treace Medical Concepts is focused on advancing surgical treatment for bunions and related midfoot deformities, with its flagship procedures being Lapiplasty® and Adductoplasty® [4] - Approximately 67 million Americans are affected by bunions, with an estimated 1.1 million being annual surgical candidates [4] - The company has developed the Lapiplasty® 3D Bunion Correction® System, which addresses the root cause of bunions by correcting deformities in all three planes and stabilizing the affected joint [4] - Treace has also introduced the Adductoplasty® Midfoot Correction System and the Hammertoe PEEK Fixation System to address various foot deformities [4] - The company is expanding its product offerings with the SpeedPlate™ Rapid Compression Implants, which provide versatile fixation options for various surgical procedures [4]

NEW YORK, May 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ: TMCI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Treace and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 7, 2024 ...

Treace Medical Concepts Inc (NASDAQ:TMCI) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Julie Dewey - Chief Communications & Investor Relations Officer John Treace - Founder & CEO Mark Hair - Chief Financial Officer Conference Call Participants Richard Newitter - Truist Securities Drew Ranieri - Morgan Stanley Harrison Parsons - Stephens Simon Nigan - UBS Operator Good day, and thank you for standing by, and welcome to the Treace Medical Concepts First Quarter 2024 Earnings Co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40355 Treace Medical Concepts, Inc. (Exact name of registrant as specified in its charter) Delaware 47-1052611 (State or ...

Financial Performance - First quarter 2024 revenue was $51.1 million, a 21% increase from $42.2 million in the same period of 2023[4] - Net loss attributable to common stockholders for the first quarter 2024 was ($18.7) million, or ($0.30) per share, compared to ($13.5) million, or ($0.23) per share, for the same period in 2023[8] - Adjusted EBITDA loss improved to ($8.3) million in the first quarter 2024, compared to a loss of ($10.0) million for the same period in 2023[5] - The company expects full-year 2024 revenue to be between $201 million and $211 million, a growth of 7% to 13% compared to 2023[10] - The company aims for a significant improvement in Adjusted EBITDA for full-year 2024, anticipating approximately 50% improvement compared to 2023[10] Operating Expenses and Liabilities - Total operating expenses increased to $59.9 million in the first quarter 2024, up from $47.9 million in the first quarter 2023[7] - Total current liabilities rose from $45,033 million as of December 31, 2023, to $47,049 million as of March 31, 2024, an increase of 4.5%[25] - Accounts payable increased significantly from $11,835 million in December 2023 to $21,149 million in March 2024, reflecting a rise of 78.5%[25] - The company reported a depreciation and amortization expense of $1,909 million for Q1 2024, up from $924 million in Q1 2023, marking a 106.5% increase[27] Cash and Assets - Cash, cash equivalents, marketable securities, and investment receivable totaled $112.1 million as of March 31, 2024[9] - Cash and cash equivalents decreased from $12,982 million at the end of 2023 to $9,334 million by March 31, 2024, a reduction of 28.5%[27] - Total assets decreased from $251,907 million as of December 31, 2023, to $242,726 million as of March 31, 2024, a decline of approximately 3.5%[25] Equity and Capital - The company’s additional paid-in capital increased from $271,973 million to $279,433 million, reflecting a growth of 2.7%[25] - The total stockholders' equity decreased from $137,938 million at the end of 2023 to $126,391 million by March 31, 2024, a decline of approximately 8.4%[25] Product Development - The company plans to introduce two innovative 3D MIS Osteotomy solutions later this year to enhance its product offerings[3] - The patent portfolio expanded to 63 granted U.S. patents, with an additional 20 granted patents worldwide and 83 pending U.S. patent applications[5] Cash Flow - Cash flows used in operating activities improved to $(7,221) million in Q1 2024 from $(17,259) million in Q1 2023, a positive change of 58%[27]

Treace Medical Concepts Inc (NASDAQ:TMCI) Q4 2023 Results Conference Call February 27, 2024 4:30 PM ET Company Participants Julie Dewey - Chief Communications & Investor Relations Officer John Treace - CEO, Founder & Director Mark Hair - Chief Financial Officer Conference Call Participants Drew Ranieri - Morgan Stanley Robbie Marcus - JPMorgan Rick Wise - Stifel Simon Nigan - UBS Richard Newitter - Truist Securities Ryan Zimmerman - BTIG George Sellers - Stephens Operator Good day, and thank you for standin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number 001-40355 TREACE MEDICAL CONCEPTS, INC. (Exact name of Registrant as specified in its Charter) Delaware 47-1052 ...